The Open Global Health Library provides a set of interesting research compounds free of charge. You decide which infectious disease you are targeting and which experimental setup you are using.
By providing this compound library free of charge we aim to support researchers worldwide to identify new approaches to treat life-threatening infectious diseases especially in low and middle income countries. We provide a preselected collection of small molecules as chemical starting points to enable drug screening against the infectious disease of your interest and to enable you to identify the next life-changing infectious disease drug.
Praziquantel is on the WHO list of essential medicines for the treatment of parasitic worms (helminths) infections such as Schistosomiasis. The structure stems from a library of compounds originally developed by Merck KGaA, Darmstadt, Germany as potential antipsychotics and then provided to Bayer for testing against worm parasites. Thus, repurposing led to the discovery of EMBAY-8440 in 1972 which was further co-developed by both companies to become Praziquantel, an anthelmintic drug approved in 1980. Engage with the Open Global Health Library to write the next success story!
Our library contains pre-selected R&D compounds. We invite you to use these compounds in your assay systems for your infectious disease research and you will be the full owner of your results. The compounds cover a wide range of molecular targets and could potentially interact with and modulate the activity of e.g. enzymes, receptors or transporters you are evaluating.
All compounds are small molecules (no biologicals), which will be supplied in 30 µl in a concentration of 10 mM in a solution of dimethyl sulfoxide (DMSO).
We invite researchers from universities, research institutes and private companies to apply for our Open Global Health Library and to use our compound library for research and development purposes only.
Anyone doing research in infectious diseases is invited to contact us via open.innovation@emdgroup.com.
Please be aware that this program is not open to healthcare organizations (HCO).
If you are interested in the Open Global Health Library, please contact us via open.innovation@emdgroup.com with a brief outline of your intended research and the infectious disease you are targeting. In reply, we send you our Open Global Health Library agreement. Once the agreement is signed, we send you the compound library.
Please note that the agreement needs to be executed between us and your respective institution (e.g. university or company).
Compound structures and a certain set of further information will be provided upon sharing your results with us. Upon request we may also provide further compounds for additional experiments.
If you are interested in testing our compounds in other therapeutic areas than human infectious diseases, please have a look at our Biopharma Mini Library or contact us directly (open.innovation@emdgroup.com).
The Open Global Health Library is an open innovation initiative to support research and development in infectious diseases.
We welcome you to share your results with us for follow-ups. If you intend to publish your results in scientific journals, we ask you to acknowledge Merck KGaA, Darmstadt, Germany and the Open Global Health Library in your upcoming publication.
| Link | ||
|---|---|---|
Identification of potent and orally efficacious phosphodiesterase inhibitors in Cryptosporidium parvum-infected immunocompromised male mice 2023, Ajiboye, J, Teixeira, JE [...], Meyers, MJ, Huston, CD, Nature Communications. |
https://doi.org/10.1038/s41467-024-52658-y |
Access to the Open Global Health Library
